RhE/e (RHCE) Antigen Genotyping
Also known as: RHE GENO
Use
The RhE/e (RHCE) Antigen Genotyping test is used to determine the RhE/e genotype of a parental or neonatal sample. This test is crucial in assessing the risk of alloimmune hemolytic disease, which occurs due to erythrocyte alloimmunization. This can lead to hemolytic transfusion reactions or hemolytic disease of the fetus and newborn (HDFN). Understanding the RhE/e genotype helps in predicting the expression of Rh antigens, informing clinical decisions related to blood transfusions and maternal-fetal compatibility.
Special Instructions
Informed consent for genetic testing is required for New York patients. The test report provides a detailed interpretation, including genotype and predicted antigen expression. Any abnormal findings should be discussed with a genetic counselor. Consent forms are available online.
Limitations
The RhE/e (RHCE) Antigen Genotyping assay may not detect rare nucleotide changes that result in altered or partial antigen expression, nor null phenotypes. Extreme variation in the Rh locus can occasionally hinder genotype prediction. The test may produce false-negative results due to RHCE-D-CE fusion genes or inconclusive results in patients who have undergone hematopoietic stem cell transplants. Abnormal signal intensities might result in indeterminate genotyping results.
FDA ApprovedNew York Approved
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 31208-2
- 48030-1
Result Turnaround Time
3-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender (K2EDTA), pink (K2EDTA)
Storage Instructions
Refrigerated.
Causes for Rejection
Yellow (ACD solution A or B); plasma or serum. Specimens collected in sodium heparin tubes. Frozen specimens in glass collection tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 1 week |
| Frozen | 1 month |